BlackRock, Inc. 13D and 13G filings for Neoleukin Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-07-08 4:57 pm Sale | 2022-06-30 | 13G | Neoleukin Therapeutics, Inc. NLTX | BlackRock Inc. BLK | 45,542 2.100% | -84,691 (-65.03%) | Filing |
| 2022-02-02 7:18 pm Sale | 2021-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | BlackRock Inc. BLK | 130,232 6.100% | -4,013 (-2.99%) | Filing |